- Previous Close
176.95 - Open
177.02 - Bid 177.25 x 800
- Ask 177.99 x 1100
- Day's Range
176.85 - 180.19 - 52 Week Range
137.65 - 207.32 - Volume
12,462,983 - Avg. Volume
5,615,338 - Market Cap (intraday)
312.89B - Beta (5Y Monthly) 0.61
- PE Ratio (TTM)
61.69 - EPS (TTM)
2.87 - Earnings Date Jan 31, 2025 - Feb 4, 2025
- Forward Dividend & Yield 6.56 (3.71%)
- Ex-Dividend Date Jan 15, 2025
- 1y Target Est
204.74
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
www.abbvie.com50,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: ABBV
View MorePerformance Overview: ABBV
Trailing total returns as of 11/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ABBV
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ABBV
View MoreValuation Measures
Market Cap
312.70B
Enterprise Value
376.49B
Trailing P/E
61.66
Forward P/E
14.93
PEG Ratio (5yr expected)
0.42
Price/Sales (ttm)
5.65
Price/Book (mrq)
51.84
Enterprise Value/Revenue
6.78
Enterprise Value/EBITDA
20.66
Financial Highlights
Profitability and Income Statement
Profit Margin
9.22%
Return on Assets (ttm)
7.72%
Return on Equity (ttm)
56.41%
Revenue (ttm)
55.53B
Net Income Avi to Common (ttm)
5.08B
Diluted EPS (ttm)
2.87
Balance Sheet and Cash Flow
Total Cash (mrq)
7.29B
Total Debt/Equity (mrq)
1,174.81%
Levered Free Cash Flow (ttm)
17.74B